Roth Capital initiated coverage of HeartBeam (BEAT) with a Buy rating and $4 price target The company is developing a credit-card-sized, cable-free cardiac device that synthesizes a 12-lead electrocardiogram, the analyst tells investors in a research note. The firm expects FDA clearance in the “coming days” that will initially focus on advanced cardiac arrhythmias within the concierge medicine market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAT:
- HeartBeam (NASDAQ: BEAT) Schedules Third Quarter 2025 Conference Call for November 13
- HeartBeam (NASDAQ: BEAT) Partners with HeartNexus to Deliver 24/7 Remote Cardiology Services and Real-Time ECG Interpretation
- HeartBeam partners with HeartNexus
- HeartBeam (NASDAQ: BEAT) Combining Portability and Precision to Redefine Future of Cardiac Care
- HeartBeam (NASDAQ: BEAT) on the Beat of Cardiac Innovation